{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T08:53:36Z","timestamp":1780563216897,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clinbiochem.2025.110992","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T20:50:33Z","timestamp":1755550233000},"page":"110992","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Gaps in guideline adherence: evaluating HLA-B*57:01 screening for abacavir sensitivity and the implementation of evidence-based HIV care"],"prefix":"10.1016","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4214-2467","authenticated-orcid":false,"given":"Lisa V.","family":"Kalman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Lin A.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Buchacz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rex","family":"Astles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"O\u2019Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.clinbiochem.2025.110992_b0005","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1001\/jama.2019.6587","article-title":"Screening for HIV infection: US preventive services task force recommendation statement","volume":"321","author":"US Preventive Services Task Force","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.clinbiochem.2025.110992_b0010","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae479","article-title":"Primary care guidance for providers of care for persons with human immunodeficiency virus: 2024 update by the HIV Medicine Association of the Infectious Diseases Society of America","author":"Horberg","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.clinbiochem.2025.110992_b0015","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/what-start-initial-antiretroviral?view=full: Department of Health and Human Services; Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/what-start-initial-antiretroviral?view=full."},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.110992_b0020","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/infdis\/jix595","article-title":"Laboratory testing of a cohort of commercially insured users of HIV preexposure prophylaxis in the United States, 2011-2015","volume":"217","author":"Huang","year":"2018","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.110992_b0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/QAI.0000000000000652","article-title":"Disparities in initiation of combination antiretroviral treatment and in virologic suppression among patients in the HIV outpatient study, 2000-2013","volume":"70","author":"Novak","year":"2015","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"9","key":"10.1016\/j.clinbiochem.2025.110992_b0030","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/ajh\/hpae048","article-title":"Hypertension prevalence and control among people with and without HIV - United States, 2022","volume":"37","author":"Weng","year":"2024","journal-title":"Am. J. Hypertens."},{"issue":"15","key":"10.1016\/j.clinbiochem.2025.110992_b0035","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jama.282.15.1458","article-title":"Why don\u2019t physicians follow clinical practice guidelines? A framework for Improvement","volume":"282","author":"Cabana","year":"1999","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.clinbiochem.2025.110992_b0040","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0149-2918(01)80132-6","article-title":"Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir","volume":"23","author":"Hetherington","year":"2001","journal-title":"Clin. Ther."},{"issue":"6","key":"10.1016\/j.clinbiochem.2025.110992_b0045","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.clinbiochem.2025.110992_b0050","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jama.300.5.555","article-title":"Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel","volume":"300","author":"Hammer","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.clinbiochem.2025.110992_b0055","unstructured":"European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/ziagen-epar-medicine-overview_en.pdf https:\/\/www.ema.europa.eu\/en\/documents\/overview\/ziagen-epar-medicine-overview_en.pdf."},{"key":"10.1016\/j.clinbiochem.2025.110992_b0060","unstructured":"Food and Drug Administration. Table of Pharmacogenetic Associations https:\/\/www.fda.gov\/medical-devices\/precision-medicine\/table-pharmacogenetic-associations."},{"key":"10.1016\/j.clinbiochem.2025.110992_b0065","unstructured":"Food and Drug Administration: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/020977s035,020978s038lbl.pdf."},{"key":"10.1016\/j.clinbiochem.2025.110992_b0070","unstructured":"North American AIDS Cohort Collaboration on Research and Design. https:\/\/naaccord.org\/."},{"issue":"5","key":"10.1016\/j.clinbiochem.2025.110992_b0075","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/17512433.2019.1597706","article-title":"The role of pharmacogenomics in adverse drug reactions","volume":"12","author":"Cacabelos","year":"2019","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.clinbiochem.2025.110992_b0080","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.pharmthera.2019.01.002","article-title":"Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity","volume":"197","author":"Lauschke","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.110992_b0085","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11030179","article-title":"Pharmacogenomic biomarkers in US FDA-approved drug labels (2000-2020)","volume":"11","author":"Kim","year":"2021","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.clinbiochem.2025.110992_b0090","first-page":"1","article-title":"Medical genetics summaries","volume":"1","author":"Pratt","year":"2012","journal-title":"Bethesda (MD)"},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.110992_b0095","first-page":"65","article-title":"Pharmacogenetics: a general review on progress to date","volume":"124","author":"Daly","year":"2017","journal-title":"Br. Med. Bull."},{"issue":"7","key":"10.1016\/j.clinbiochem.2025.110992_b0100","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/phar.1278","article-title":"Abacavir pharmacogenetics\u2013from initial reports to standard of care","volume":"33","author":"Martin","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.clinbiochem.2025.110992_b0105","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jaci.2015.06.024","article-title":"New approaches for predicting T cell-mediated drug reactions: a role for inducible and potentially preventable autoimmunity","volume":"136","author":"Michels","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"issue":"10374","key":"10.1016\/j.clinbiochem.2025.110992_b0110","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0140-6736(22)01841-4","article-title":"A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study","volume":"401","author":"Swen","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clinbiochem.2025.110992_b0115","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.5345","article-title":"Projected prevalence of actionable pharmacogenetic variants and level a drugs prescribed among US veterans health administration pharmacy users","volume":"2","author":"Chanfreau-Coffinier","year":"2019","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.110992_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12981-019-0217-3","article-title":"HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA((R)) observational database: a cohort study","volume":"16","author":"Mounzer","year":"2019","journal-title":"AIDS Res. Ther."},{"key":"10.1016\/j.clinbiochem.2025.110992_b0125","unstructured":"Observational Health Data Sciences and Informatics https:\/\/www.ohdsi.org\/data-standardization\/."},{"key":"10.1016\/j.clinbiochem.2025.110992_b0130","unstructured":"Food and Drug Administration. https:\/\/www.fda.gov\/drugs\/hiv-treatment\/hiv-treatment-information-adults."},{"key":"10.1016\/j.clinbiochem.2025.110992_b0135","unstructured":"HIV.gov. U.S, Statistics (2025). https:\/\/www.hiv.gov\/hiv-basics\/overview\/data-and-trends\/statistics."},{"issue":"2","key":"10.1016\/j.clinbiochem.2025.110992_b0140","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.37765\/ajmc.2025.89683","article-title":"Medical policy determinations for pharmacogenetic tests among US health plans","volume":"31","author":"Patel","year":"2025","journal-title":"Am. J. Manag. Care"},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.110992_b0145","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/clpt.2011.355","article-title":"Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing","volume":"91","author":"Martin","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.clinbiochem.2025.110992_b0150","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/clpt.2014.38","article-title":"Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing: 2014 update","volume":"95","author":"Martin","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.clinbiochem.2025.110992_b0155","unstructured":"Royal Dutch Pharmacists Association (KNMP). Pharmacogenetic Guidelines Abacavir \u2013 HLA-B*5701. http:\/\/kennisbank.knmp.nl http:\/\/kennisbank.knmp.nl."},{"key":"10.1016\/j.clinbiochem.2025.110992_b0160","doi-asserted-by":"crossref","unstructured":"In: Graham R, Mancher M, Miller Wolman D, Greenfield S, Steinberg E, editors. Clinical Practice Guidelines We Can Trust. Washington (DC)2011.","DOI":"10.17226\/13058"},{"key":"10.1016\/j.clinbiochem.2025.110992_b0165","unstructured":"Coffey S. Immediate ART Initiation & Restart: Guide for Clinicians 2023. https:\/\/aidsetc.org\/sites\/default\/files\/media\/document\/2023-06\/ncrc-rapid-art-full.pdf."},{"issue":"12","key":"10.1016\/j.clinbiochem.2025.110992_b0170","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1258\/jrsm.2011.110180","article-title":"The answer is 17 years, what is the question: understanding time lags in translational research","volume":"104","author":"Morris","year":"2011","journal-title":"J. R. Soc. Med."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912025001213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912025001213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T13:32:05Z","timestamp":1766842325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912025001213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":34,"alternative-id":["S0009912025001213"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2025.110992","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gaps in guideline adherence: evaluating HLA-B*57:01 screening for abacavir sensitivity and the implementation of evidence-based HIV care","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2025.110992","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of The Canadian Society of Clinical Chemists.","name":"copyright","label":"Copyright"}],"article-number":"110992"}}